Baird’s Insys Therapeutics, Inc. INSY Stock Holding History

Baird’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-107,026	Closed	-$2.08M	–	1340
2014 Q3	$2.08M	Buy	+107,026	New	+$1.68M	0.03%	458

Other funds holding INSY

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Baird's INSY Position: Q4 2014 in Review

Baird sold out of Insys Therapeutics, Inc. (INSY) in Q4 2014, closing a stake of 107,026 shares — an estimated $2.08M sold.

Baird first reported a position in INSY in Q3 2014 and held it in 1 quarter. The position peaked at $2.08M in Q3 2014. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2014.

Baird reported no remaining Insys Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
Baird sold 107,026 Insys Therapeutics, Inc. shares in Q4 2014, an estimated $2.08M.
Baird first reported a position in Insys Therapeutics, Inc. in Q3 2014 and held it in 1 quarter.
Baird's Insys Therapeutics, Inc. position peaked at $2.08M in Q3 2014.
113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2014.

Based on Baird's 13F filing for Q4 2014, filed 12 Feb 2015.